PHARMACOPEIA INC. PCOP $ 1.06 Change: +0.11 +10.38% | Volume: 410,489
Sponsored by Click here!

PHARMACOPEIA IN - Fundamental Profile

Company Information

Ticker Symbol: PCOP
Exchange: NASD
Contact Info: P.O. Box 5350 Princeton NJ 08543-5350 609-452-3600
CEO/President: Leslie J. Browne Ph.D.
Industry: Medical - Drugs / Standard Industry Code: 8731
Description: Pharmacopeia is committed to discovering and developing novel therapeutics to address significant medical needs. The Company has a broad portfolio advancing toward clinical validation, both independently and with partners. Pharmacopeia\'s most advanced internal program is a dual-acting angiotensin and endothelin receptor antagonist for hypertension and diabetic kidney disease for which Phase 1 clinical trials are underway. Other internal proprietary programs address primarily immunoregulation. Pharmacopeia\'s collaborative efforts have resulted in a portfolio that includes one partnered program currently in Phase 2 clinical trials targeting chronic obstructive pulmonary disease and four partnered programs in Phase 1 clinical trials targeting rheumatoid arthritis, oncology, metabolic and inflammatory diseases. Four additional partnered compounds are in preclinical development.

Share Information

Shares Outstanding: 29,780 (000) Market Value: 29,780 ($000)
Percentage of Inst.Shareholders: 60.19% Number of Inst.Shareholders: 5.61%
Last Quarter Sales: 5.92 ($Mil.) Last Quarter Net Income: -10.82 ($Mil.)
Last Quarter EPS: -0.29 P/E Ratio: 0
Most Recent Earnings: Earnings Per Share: -1.94
Most Recent Split: Annual Dividend Rate: 0
Most Recent Dividend: Annual Dividend Yield: 0%
Data Provided By Barchart.com
CoreData does not represent, warrant, or guarantee completeness, accuracy or timeliness of its data, and shall have no liability of any kind whatsoever to any party on account of any incompleteness of, inaccuracies in or untimeliness of the CoreData content provided hereunder, or for any delay in reporting such data. CoreData expressly disclaims all warranties of fitness of the CoreData content or computations and analyses thereof for a particular purpose or use.
advertisement

Top Competitors

PFIZER INC -26.60 16.43
JOHNSON AND JOH -14.40 58.58
BRISTOL MYERS S -21.50 20.70
SCHERING PLOUGH -38.30 16.81
MERCK CO INC -53.90 26.72